Business DevelopmentThe signaling by the company of a doubling down on its core cardiovascular expertise and the discontinuation of the Sjögren’s disease program represents a positive business development decision.
Financial HealthKiniksa Pharmaceuticals ended the year with $243.6 million of cash and equivalents and expects to be cash flow positive while funding clinical trials, indicating strong financial health.
Market ShareArcalyst market share should continue to grow in earlier lines of treatment, with encouraging trends in expected utilization in 1st and 2nd recurrence points.